Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities... Show more
CME Group operates the world's leading derivatives marketplace, offering futures and options across interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals. Its structural advantage is a deep liquidity moat: a "liquidity begets liquidity" dynamic that makes it difficult for competitors to attract volume away from its tightly priced order books. That moat is reinforced by a single, vertically integrated clearinghouse that enables cross-margining — letting clients offset margin requirements across asset classes, which lowers their capital costs and locks them into the ecosystem.
Interest-rate products remain the profit engine, with CME holding a dominant position in U.S. Treasury and SOFR-linked futures (SOFR is the Secured Overnight Financing Rate, the benchmark that replaced LIBOR). The 2018 acquisition of NEX added BrokerTec, a U.S. Treasury cash and repo platform, and EBS, a spot foreign-exchange venue, extending CME's reach beyond listed derivatives into cash fixed income and FX. Management is now pushing further into adjacent markets — credit, leveraged loans, and 24/7 precious metals — to diversify away from a purely rate-and-equity revenue base while strengthening its pricing power.
The most consequential upcoming catalyst is the phased implementation of U.S. Treasury central clearing mandates, which require a broader set of Treasury cash and repo transactions to be centrally cleared. CME's new Treasury clearing venue is positioned to capture a share of this activity, and its recently expanded cross-margining arrangement with DTCC/FICC — now extended to end-user clients — could materially improve capital efficiency for institutions managing Treasury and interest-rate futures positions together.
Product innovation adds further catalysts. CME launched 24/7 crypto trading, filed to convert its micro equity index options to financially settled contracts, introduced the first exchange-traded leveraged loan index futures, and is pursuing tokenized cash pilots and a potential stablecoin license. Management also guided to full-year 2026 adjusted expense of $1.695 billion, signaling continued investment in technology and a new Dallas testing environment ahead of cloud migration for select agricultural products.
On the analyst front, sentiment is genuinely divided. Morgan Stanley maintains an Overweight (Buy-equivalent) rating with a $330 price target, while Piper Sandler ($295) and Deutsche Bank ($300) also sit in the bullish camp. By contrast, J.P. Morgan ($250), Goldman Sachs ($243), and Bank of America ($230) hold Sell ratings, citing regulatory and competitive pressures alongside valuation. The consensus rating is "Hold," with average price targets clustering near $284 to $298 — modest upside that reflects both record trading volumes and concerns that peak activity may already be priced in.
CME's revenue is tightly coupled to trading activity, so macroeconomic uncertainty is, paradoxically, a tailwind. When investors disagree about the path of interest rates, inflation, or geopolitics, hedging demand rises. In 2026, elevated inflation, divided Federal Reserve votes on the direction of policy, and geopolitical shocks have kept average daily volume (ADV) at or near records — a dynamic that directly feeds clearing and transaction fees.
Interest rates are the dominant variable. Whether rates rise or fall matters less than the velocity of repricing; record global debt levels sustain structural demand for rate derivatives regardless of direction. Commodity prices and energy volatility drive the energy and metals complexes, while technology adoption — including the "retailization" of derivatives through micro contracts and mobile access — expands the addressable customer base. The regulatory climate is broadly supportive, with clearing mandates favoring incumbent infrastructure, though competition from non-U.S. perpetual platforms and rival venues such as FMX remains a structural watch item.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality, giving investors a structured way to monitor momentum alongside fundamental and macro analysis. For those tracking how rate volatility and clearing mandates might shape CME's trajectory, the Trend Prediction Engine offers a complementary, data-driven lens worth exploring.
Looking through 2026 and beyond, CME's trajectory hinges on a few structural themes. The Treasury clearing build-out represents the clearest long-term growth opportunity, potentially converting regulatory change into durable, higher-volume clearing revenue. Capital efficiency initiatives — particularly cross-margining and the tokenization of cash and collateral — could deepen client engagement and support margin sustainability across the existing fee base.
Technology transitions are a double-edged sword. Cloud migration, 24/7 trading, and prediction markets expand reach but require ongoing expense, and management has signaled continued investment. Competition remains the primary structural risk: rival platforms, non-U.S. venues, and any erosion of the liquidity moat could pressure both volumes and the average rate per contract. Consensus analyst expectations imply moderate forward growth, with 2026 earnings-per-share estimates around $12.25 and 2027 estimates near $12.92, but the wide dispersion in price targets underscores genuine uncertainty about how much of CME's recent volume surge is durable versus cyclical.
Ultimately, CME's future outlook depends less on any single event than on its ability to keep converting regulatory tailwinds, product innovation, and its liquidity advantage into compounding, fee-generating volume across the full interest-rate cycle.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CME has been loosely correlated with ICE. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CME jumps, then ICE could also see price increases.
| Ticker / NAME | Correlation To CME | 1D Price Change % | ||
|---|---|---|---|---|
| CME | 100% | +0.28% | ||
| ICE - CME | 49% Loosely correlated | -0.64% | ||
| TW - CME | 45% Loosely correlated | -0.59% | ||
| MKTX - CME | 35% Loosely correlated | -0.05% | ||
| NDAQ - CME | 35% Loosely correlated | -0.86% | ||
| MSCI - CME | 25% Poorly correlated | -1.27% | ||
More | ||||
| Ticker / NAME | Correlation To CME | 1D Price Change % |
|---|---|---|
| CME | 100% | +0.28% |
| Financial Publishing/Services industry (14 stocks) | 13% Poorly correlated | -0.61% |
| Commercial Services industry (90 stocks) | 1% Poorly correlated | -1.58% |
an operator of securities and commodity exchanges
Industry FinancialPublishingServices
CME moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 63 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on CME as a result. In 58 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for CME just turned positive on October 08, 2026. Looking at past instances where CME's MACD turned positive, the stock continued to rise in 26 of 48 cases over the following month. The odds of a continued upward trend are 54%.
Following a +3.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in 176 of 346 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for CME crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 46%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 41%.
CME broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CME entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 41 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.569) is normal, around the industry mean (-5.093). P/E Ratio (22.327) is within average values for comparable stocks, (25.252). CME's Projected Growth (PEG Ratio) (4.578) is very high in comparison to the industry average of (1.780). CME has a moderately high Dividend Yield (0.043) as compared to the industry average of (0.018). CME's P/S Ratio (14.535) is slightly higher than the industry average of (7.166).